DNA damage_Role of Brca1 and Brca2 in DNA repair

No Pathway Network information available for DNA damage_Role of Brca1 and Brca2 in DNA repair

Pathways in the DNA damage_Role of Brca1 and Brca2 in DNA repair SuperPath

#	Name	Source	Genes
1	DNA damage_Role of Brca1 and Brca2 in DNA repair	GeneGo (Thomson Reuters)	ATF1 ATM ATR BARD1 BRCA1 BRCA2 BRIP1 CHEK2 DDB2 FANCD2 FANCL H2AX MDC1 MLH1 MRE11 MSH2 MSH3 MSH6 NBN NTHL1 PCNA POLB POLR2A POLR2B POLR2C POLR2D POLR2E POLR2F POLR2G POLR2H POLR2I POLR2J POLR2J2 POLR2K POLR2L RAD50 RAD51 TP53 TP53BP1 XPC (see all 40) (see less)

Ordered by rank within the SuperPath, via the multiplicity of each gene in the constituent pathways

#	Symbol	Description	Category	# Related Pathways
1	ATF1	Activating Transcription Factor 1	Protein Coding	1
2	ATM	ATM Serine/Threonine Kinase	Protein Coding	1
3	ATR	ATR Checkpoint Kinase	Protein Coding	1
4	BARD1	BRCA1 Associated RING Domain 1	Protein Coding	1
5	BRCA1	BRCA1 DNA Repair Associated	Protein Coding	1
6	BRCA2	BRCA2 DNA Repair Associated	Protein Coding	1
7	DDB2	Damage Specific DNA Binding Protein 2	Protein Coding	1
8	FANCD2	FA Complementation Group D2	Protein Coding	1
9	MSH6	MutS Homolog 6	Protein Coding	1
10	H2AX	H2A.X Variant Histone	Protein Coding	1
11	MLH1	MutL Homolog 1	Protein Coding	1
12	MRE11	MRE11 Double Strand Break Repair Nuclease	Protein Coding	1
13	MSH2	MutS Homolog 2	Protein Coding	1
14	MSH3	MutS Homolog 3	Protein Coding	1
15	NBN	Nibrin	Protein Coding	1
16	NTHL1	Nth Like DNA Glycosylase 1	Protein Coding	1
17	PCNA	Proliferating Cell Nuclear Antigen	Protein Coding	1
18	POLB	DNA Polymerase Beta	Protein Coding	1
19	POLR2A	RNA Polymerase II Subunit A	Protein Coding	1
20	POLR2B	RNA Polymerase II Subunit B	Protein Coding	1
21	POLR2C	RNA Polymerase II Subunit C	Protein Coding	1
22	POLR2D	RNA Polymerase II Subunit D	Protein Coding	1
23	POLR2E	RNA Polymerase II, I And III Subunit E	Protein Coding	1
24	POLR2F	RNA Polymerase II, I And III Subunit F	Protein Coding	1
25	POLR2G	RNA Polymerase II Subunit G	Protein Coding	1
26	POLR2H	RNA Polymerase II, I And III Subunit H	Protein Coding	1
27	POLR2I	RNA Polymerase II Subunit I	Protein Coding	1
28	POLR2J	RNA Polymerase II Subunit J	Protein Coding	1
29	POLR2K	RNA Polymerase II, I And III Subunit K	Protein Coding	1
30	POLR2L	RNA Polymerase II, I And III Subunit L	Protein Coding	1
31	RAD51	RAD51 Recombinase	Protein Coding	1
32	TP53	Tumor Protein P53	Protein Coding	1
33	TP53BP1	Tumor Protein P53 Binding Protein 1	Protein Coding	1
34	XPC	XPC Complex Subunit, DNA Damage Recognition And Repair Factor	Protein Coding	1
35	MDC1	Mediator Of DNA Damage Checkpoint 1	Protein Coding	1
36	RAD50	RAD50 Double Strand Break Repair Protein	Protein Coding	1
37	CHEK2	Checkpoint Kinase 2	Protein Coding	1
38	FANCL	FA Complementation Group L	Protein Coding	1
39	BRIP1	BRCA1 Interacting DNA Helicase 1	Protein Coding	1
40	POLR2J2	RNA Polymerase II Subunit J2	Protein Coding	1

Disorders associated with DNA damage_Role of Brca1 and Brca2 in DNA repair SuperPath

according to GeneCards Suite gene sharing

#	Disorder	Type	Genes	Score
1	Breast cancer	Enrichment	ATM, BARD1, BRCA1, BRCA2, BRIP1, CHEK2, MLH1, MRE11, MSH2, MSH6, NBN, RAD50, RAD51, TP53	16.00
2	Colorectal cancer	Enrichment	ATM, BRCA1, BRCA2, BRIP1, CHEK2, MLH1, MSH2, MSH6, TP53	16.00
3	Ovarian cancer	Enrichment	ATM, BARD1, BRCA1, BRCA2, BRIP1, CHEK2, FANCD2, MRE11, MSH2, MSH6, NBN, RAD50, TP53, XPC	16.00
4	Pancreatic cancer	Enrichment	ATM, BRCA1, BRCA2, BRIP1, CHEK2, NBN, TP53	16.00
5	Breast-ovarian cancer, familial 1	Enrichment	ATM, BRCA1, BRCA2, BRIP1, CHEK2, MSH2, NBN	16.00
6	Gastric cancer	Enrichment	ATM, BARD1, BRCA1, BRCA2, BRIP1, CHEK2, MLH1, MSH2, MSH6, NBN, TP53	16.00
7	Hereditary breast carcinoma	Enrichment	ATM, BARD1, BRCA1, BRCA2, BRIP1, CHEK2, MLH1, MSH2, MSH6, NBN, RAD50, RAD51, TP53	11.52
8	Prostate cancer	Enrichment	ATM, BRCA1, BRCA2, CHEK2, MSH6, NBN, TP53	11.32
9	Hereditary breast ovarian cancer syndrome	Enrichment	ATM, BARD1, BRCA1, BRCA2, BRIP1, CHEK2, MLH1, MRE11, MSH2, MSH6, NBN, RAD50, RAD51, TP53	11.24
10	Inherited cancer-predisposing syndrome	Enrichment	ATM, BARD1, BRCA1, BRCA2, BRIP1, CHEK2, MLH1, MRE11, MSH2, MSH3, MSH6, NBN, NTHL1, RAD50, TP53	11.18
11	Uterine corpus cancer	Enrichment	ATM, BRCA1, BRCA2, BRIP1, CHEK2, MSH2, MSH6	10.94
12	Endometrial cancer	Enrichment	ATM, BARD1, BRCA1, BRCA2, CHEK2, MLH1, MSH2, MSH3, MSH6	10.94
13	Lynch syndrome 1	Enrichment	ATM, CHEK2, MLH1, MSH2, MSH6	10.57
14	Fanconi anemia, complementation group a	Enrichment	BRCA1, BRCA2, BRIP1, FANCD2, FANCL, RAD51	9.16
15	Rhabdomyosarcoma	Enrichment	BRCA1, BRCA2, MSH2, MSH6, TP53	9.14
16	Colonic benign neoplasm	Enrichment	ATM, CHEK2, MLH1, MRE11	8.09
17	Lynch syndrome	Enrichment	CHEK2, MLH1, MSH2, MSH6	7.06
18	Mismatch repair cancer syndrome 1	Enrichment	MLH1, MSH2, MSH6	7.02
19	Diffuse large b-cell lymphoma	Enrichment	BRCA2, CHEK2, NBN, TP53	6.61
20	Hepatoblastoma	Enrichment	BARD1, BRCA2, MSH2, TP53	6.43
21	Bladder cancer	Enrichment	ATM, BRCA1, BRCA2, TP53	5.84
22	Familial colorectal cancer	Enrichment	MLH1, MSH2, TP53	5.55
23	Familial colorectal cancer type x	Enrichment	ATM, BRCA2, CHEK2	5.41
24	Muir-torre syndrome	Enrichment	MLH1, MSH2	5.07
25	Diffuse midline glioma, h3 k27m-mutant	Enrichment	BRCA2, BRIP1	5.07
26	Li-fraumeni syndrome 1	Enrichment	CHEK2, TP53	5.07
27	Sarcoma	Enrichment	CHEK2, TP53	5.07
28	Inflammatory breast carcinoma	Enrichment	BRCA1, BRCA2	5.07
29	Bilateral breast cancer	Enrichment	BRCA1, BRCA2	5.07
30	Gliosarcoma	Enrichment	ATM, MSH2, TP53	4.89
31	Giant cell glioblastoma	Enrichment	ATM, MSH2, TP53	4.80
32	Myeloma, multiple	Enrichment	ATM, BARD1, BRCA2, TP53	4.67
33	Esophageal atresia/tracheoesophageal fistula	Enrichment	BRCA2, BRIP1, POLR2B	4.65
34	Osteogenic sarcoma	Enrichment	CHEK2, TP53	4.60
35	Adenocarcinoma	Enrichment	ATM, TP53	4.60
36	Bone osteosarcoma	Enrichment	CHEK2, TP53	4.60
37	Hepatocellular carcinoma	Enrichment	NBN, RAD50, TP53	4.45
38	Polyposis syndrome, hereditary mixed, 1	Enrichment	BRCA1, BRCA2	4.30
39	Cholangiocarcinoma	Enrichment	BRCA1, BRCA2	4.30
40	Lynch syndrome 4	Enrichment	MSH2, MSH6	4.30
41	Nijmegen breakage syndrome-like disorder	Enrichment	MRE11, RAD50	4.30
42	Fanconi anemia, complementation group d2	Enrichment	BRIP1, FANCD2	4.07
43	Breast-ovarian cancer, familial 2	Enrichment	BRCA1, BRCA2	4.07
44	Glioblastoma	Enrichment	ATM, MSH2	4.07
45	Lung cancer	Enrichment	BRCA1, CHEK2, MLH1	3.95
46	Li-fraumeni syndrome	Enrichment	CHEK2, TP53	3.90
47	Tracheoesophageal fistula with or without esophageal atresia	Enrichment	BRCA2, BRIP1	3.52
48	Leukemia, chronic lymphocytic	Enrichment	ATM, TP53	3.42
49	Isolated tracheo-esophageal fistula	Enrichment	BRCA2, BRIP1	3.42
50	Xeroderma pigmentosum, variant type	Enrichment	DDB2, XPC	3.34
51	Wilms tumor 1	Enrichment	BRCA2, CHEK2	3.06
52	Palmoplantar keratoderma, punctate type ii	Enrichment	BRCA1	2.53
53	Fanconi anemia, complementation group j	Enrichment	BRIP1	2.53
54	Glioma susceptibility 3	Enrichment	BRCA2	2.53
55	Seckel syndrome 1	Enrichment	ATR	2.53
56	Mirror movements 2	Enrichment	RAD51	2.53
57	Fanconi anemia, complementation group r	Enrichment	RAD51	2.53
58	Bone marrow failure syndrome 5	Enrichment	TP53	2.53
59	Papilloma of choroid plexus	Enrichment	TP53	2.53
60	Basal cell carcinoma 7	Enrichment	TP53	2.53
61	Lynch syndrome 2	Enrichment	MLH1	2.53
62	Anaplastic thyroid carcinoma	Enrichment	TP53	2.53
63	Infant-type hemispheric glioma	Enrichment	BRCA1	2.53
64	Pancreatic cancer 2	Enrichment	BRCA2	2.53
65	Tumor predisposition syndrome 4	Enrichment	CHEK2	2.53
66	Ataxia-telangiectasia-like disorder 1	Enrichment	MRE11	2.53
67	Cutaneous telangiectasia and cancer syndrome, familial	Enrichment	ATR	2.53
68	Ataxia-telangiectasia-like disorder 2	Enrichment	PCNA	2.53
69	Familial adenomatous polyposis 3	Enrichment	NTHL1	2.53
70	Endometrial serous adenocarcinoma	Enrichment	ATM	2.53
71	Ductal carcinoma in situ	Enrichment	TP53	2.53
72	Fanconi anemia, complementation group l	Enrichment	FANCL	2.53
73	Mismatch repair cancer syndrome 2	Enrichment	MSH2	2.53
74	Leiomyosarcoma	Enrichment	CHEK2	2.53
75	Rectal benign neoplasm	Enrichment	MSH2	2.53
76	Thyroid gland undifferentiated carcinoma	Enrichment	TP53	2.53
77	Small-cell carcinoma of the ovary of hypercalcemic type	Enrichment	TP53	2.53
78	Ascending colon cancer	Enrichment	MSH2	2.53
79	Diffuse pediatric-type high-grade glioma, h3-wildtype and idh-wildtype	Enrichment	TP53	2.53
80	B-cell non-hodgkin lymphoma	Enrichment	ATM	2.53
81	Choroid plexus cancer	Enrichment	TP53	2.53
82	Ovarian cyst	Enrichment	MSH2	2.53
83	Pleomorphic xanthoastrocytoma	Enrichment	TP53	2.53
84	Familial cutaneous telangiectasia and oropharyngeal predisposition cancer syndrome	Enrichment	ATR	2.53
85	Primary peritoneal carcinoma	Enrichment	BRCA1	2.53
86	Adrenocortical carcinoma, hereditary	Enrichment	TP53	2.23
87	Xeroderma pigmentosum, complementation group c	Enrichment	XPC	2.23
88	Cervical cancer	Enrichment	TP53	2.23
89	Vacterl association, x-linked, with or without hydrocephalus	Enrichment	FANCL	2.23
90	Xeroderma pigmentosum, complementation group e	Enrichment	DDB2	2.23
91	Waardenburg syndrome, type 4c	Enrichment	POLR2F	2.23
92	Lymphoma, hodgkin, classic	Enrichment	TP53	2.23
93	Congenital heart defects, multiple types, 3	Enrichment	CHEK2	2.23
94	Xeroderma pigmentosum, complementation group a	Enrichment	XPC	2.23
95	Fanconi anemia, complementation group s	Enrichment	BRCA1	2.23
96	Cardiac valvular dysplasia, x-linked	Enrichment	ATM	2.23
97	Pancreatic cancer 4	Enrichment	BRCA1	2.23
98	Ovarian cancer 1	Enrichment	BRIP1	2.23
99	Microcephaly and chorioretinopathy, autosomal recessive, 3	Enrichment	TP53BP1	2.23
100	Congenital fibrosarcoma	Enrichment	TP53	2.23
101	High grade glioma	Enrichment	ATM	2.23
102	Fanconi anemia, complementation group d1	Enrichment	BRCA2	2.23
103	Peripheral demyelinating neuropathy, central dysmyelination, waardenburg syndrome, and hirschsprung disease	Enrichment	POLR2F	2.23
104	Cervix carcinoma	Enrichment	TP53	2.23
105	Hodgkin's lymphoma	Enrichment	TP53	2.23
106	T-cell prolymphocytic leukemia	Enrichment	ATM	2.23
107	Mismatch repair cancer syndrome 3	Enrichment	MSH6	2.23
108	Xeroderma pigmentosum group c	Enrichment	XPC	2.23
109	Peritoneum cancer	Enrichment	BRCA1	2.23
110	Microcephaly and chorioretinopathy 3	Enrichment	TP53BP1	2.23
111	Xeroderma pigmentosum group e	Enrichment	DDB2	2.23
112	Pleomorphic rhabdomyosarcoma	Enrichment	TP53	2.23
113	Neuroendocrine tumor of pancreas	Enrichment	BRCA2	2.23
114	Leukemia, acute myeloid	Enrichment	FANCD2, TP53	2.21
115	Ataxia-telangiectasia	Enrichment	ATM	2.05
116	Waardenburg syndrome, type 2a	Enrichment	POLR2F	2.05
117	Nijmegen breakage syndrome	Enrichment	NBN	2.05
118	Polycythemia vera	Enrichment	ATM	2.05
119	Nasopharyngeal carcinoma	Enrichment	TP53	2.05
120	Tumor predisposition syndrome 1	Enrichment	BRCA2	2.05
121	Lynch syndrome 5	Enrichment	MSH6	2.05
122	Familial adenomatous polyposis 4	Enrichment	MSH3	2.05
123	Koolen-de vries syndrome	Enrichment	ATM	2.05
124	Atypical teratoid rhabdoid tumor	Enrichment	TP53	2.05
125	Anaplastic astrocytoma	Enrichment	TP53	2.05
126	Squamous cell carcinoma	Enrichment	TP53	2.05
127	Cellular ependymoma	Enrichment	MSH2	2.05
128	Tanycytic ependymoma	Enrichment	MSH2	2.05
129	Papillary ependymoma	Enrichment	MSH2	2.05
130	Bap1 tumor predisposition syndrome	Enrichment	BRCA2	2.05
131	Intellectual developmental disorder with dysmorphic facies and behavioral abnormalities	Enrichment	MSH6	2.05
132	Colon adenocarcinoma	Enrichment	MSH6	2.05
133	Melanoma of soft tissue	Enrichment	ATF1	2.05
134	Clear cell ependymoma	Enrichment	MSH2	2.05
135	Mirror movements 1	Enrichment	RAD51	1.93
136	Ataxia, early-onset, with oculomotor apraxia and hypoalbuminemia	Enrichment	MRE11	1.93
137	Gaucher disease, type i	Enrichment	MSH6	1.93
138	Small cell cancer of the lung	Enrichment	TP53	1.93
139	Chordoma	Enrichment	BRCA2	1.93
140	Erythrocytosis, familial, 2	Enrichment	FANCD2	1.93
141	Thyroid cancer, nonmedullary, 1	Enrichment	TP53	1.93
142	Neurodevelopmental disorder with hypotonia and variable intellectual and behavioral abnormalities	Enrichment	POLR2A	1.93
143	Mantle cell lymphoma	Enrichment	ATM	1.93
144	Lung sarcomatoid carcinoma	Enrichment	TP53	1.93
145	Embryonal rhabdomyosarcoma	Enrichment	TP53	1.93
146	Hemoglobin c disease	Enrichment	CHEK2	1.93
147	Autosomal recessive chorioretinopathy-microcephaly syndrome	Enrichment	TP53BP1	1.93
148	Vacterl association	Enrichment	FANCL	1.93
149	Benign ependymoma	Enrichment	MSH2	1.93
150	Oculomotor apraxia	Enrichment	ATM	1.93
151	Primary ovarian insufficiency	Enrichment	CHEK2, NBN	1.88
152	Vater/vacterl association	Enrichment	FANCL	1.83
153	Von hippel-lindau syndrome	Enrichment	FANCD2	1.83
154	Hypogonadotropic hypogonadism 1 with or without anosmia	Enrichment	POLR2F	1.83
155	Rhabdomyosarcoma 2	Enrichment	TP53	1.83
156	Lymphoma	Enrichment	TP53	1.83
157	Acute megakaryocytic leukemia	Enrichment	TP53	1.83
158	Kabuki syndrome 1	Enrichment	BRCA2	1.76
159	Waardenburg syndrome, type 4a	Enrichment	POLR2F	1.76
160	Wilms tumor 5	Enrichment	CHEK2	1.76
161	Adrenocortical carcinoma	Enrichment	TP53	1.76
162	Clear cell renal cell carcinoma	Enrichment	ATM	1.76
163	Breast adenocarcinoma	Enrichment	TP53	1.76
164	Waardenburg syndrome	Enrichment	POLR2F	1.76
165	Esophageal cancer	Enrichment	TP53	1.69
166	Waardenburg syndrome, type 1	Enrichment	POLR2F	1.69
167	Squamous cell carcinoma, head and neck	Enrichment	TP53	1.69
168	Waardenburg syndrome, type 2e	Enrichment	POLR2F	1.69
169	Renal cell carcinoma, papillary, 1	Enrichment	ATM	1.69
170	Essential thrombocythemia	Enrichment	TP53	1.69
171	Gallbladder cancer	Enrichment	TP53	1.69
172	B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)	Enrichment	TP53	1.69
173	Glioma susceptibility 1	Enrichment	TP53	1.63
174	Isolated growth hormone deficiency, type ia	Enrichment	BRCA2	1.63
175	Lymphoma, non-hodgkin, familial	Enrichment	TP53	1.63
176	Polydactyly	Enrichment	BRCA2	1.58
177	Adult hepatocellular carcinoma	Enrichment	TP53	1.58
178	Primary hyperaldosteronism	Enrichment	TP53	1.58
179	Aplastic anemia	Enrichment	NBN	1.54
180	Melanoma	Enrichment	CHEK2	1.54
181	Immune deficiency disease	Enrichment	ATM	1.50
182	Leukemia, acute lymphoblastic	Enrichment	NBN	1.50
183	Myelodysplastic syndrome	Enrichment	TP53	1.50
184	Lip and oral cavity carcinoma	Enrichment	TP53	1.46
185	Premature menopause	Enrichment	NBN	1.42
186	Nk-cell enteropathy	Enrichment	CHEK2	1.42
187	Medulloblastoma	Enrichment	BRCA2	1.39
188	Lung cancer susceptibility 3	Enrichment	TP53	1.39
189	Periventricular nodular heterotopia	Enrichment	BRCA1	1.39
190	Seckel syndrome	Enrichment	ATR	1.39
191	Renal cell carcinoma, nonpapillary	Enrichment	ATM	1.36
192	Lissencephaly	Enrichment	NBN	1.22
193	Diamond-blackfan anemia 1	Enrichment	TP53	1.18
194	Kallmann syndrome	Enrichment	POLR2F	1.18
195	Hirschsprung disease 1	Enrichment	POLR2F	1.09
196	Diamond-blackfan anemia	Enrichment	TP53	1.00
197	Cerebral palsy	Enrichment	BRCA2	0.96
198	Rare genetic deafness	Enrichment	POLR2F	0.68
199	Microcephaly	Enrichment	NBN	0.51

¹ WikiPathways

² PubChem

³ R&D Systems

⁴ Reactome

⁵ GeneGo (Thomson Reuters)

⁶ QIAGEN

⁷ PharmGKB

⁸ Cell Signaling Technology

⁹ Sino Biological

¹⁰ Tocris

¹¹ MalaCards

DNA damage_Role of Brca1 and Brca2 in DNA repair

Pathway Network for DNA damage_Role of Brca1 and Brca2 in DNA repair

Member Pathways for DNA damage_Role of Brca1 and Brca2 in DNA repair

Pathways in the DNA damage_Role of Brca1 and Brca2 in DNA repair SuperPath

Associated Genes for DNA damage_Role of Brca1 and Brca2 in DNA repair

Associated Disorders for DNA damage_Role of Brca1 and Brca2 in DNA repair

Disorders associated with DNA damage_Role of Brca1 and Brca2 in DNA repair SuperPath

STRING Interaction Network for DNA damage_Role of Brca1 and Brca2 in DNA repair

Sources for DNA damage_Role of Brca1 and Brca2 in DNA repair